US2015005385A1PendingUtilityA1
Method of treating non-alcoholic fatty liver disease and steatohepatitis
Est. expiryDec 8, 2031(~5.4 yrs left)· nominal 20-yr term from priority
Inventors:Kazuko Matsuda
A61P 3/06A61P 1/16C07C 59/225A61K 31/192
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X 1 and X 2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Claims
exact text as granted — not AI-modified1 . A method of reducing hepatic fibrosis in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X 1 and X 2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X 1 and X 2 are not simultaneously oxygen atom.
2 . The method of claim 1 , in which the compound of Formula (I) is of Formula (IA)
3 . The method of claim 1 , in which the metabolite of the compound of Formula (I) is a compound of Formula (IB):
4 . The method of claim 1 , in which the compound is administered orally.
5 . The method of claim 4 , in which the compound is administered as a tablet or a capsule.
6 . The method of claim 2 , in which the compound is present in an orthorhombic polymorphic form A that is substantially free of other polymorphic forms.
7 . The method of claim 1 , in which the compound is administered as a liquid dosage form.
8 . The method of claim 1 , in which the compound is administered in an amount from 100 to 4,000 mg/day, divided into one, two, or three portions.
9 . A method of reducing damage to liver cells in a patient suffering from non-alcoholic steatohepatitis (NASH) comprising administering to a patient in need thereof an effective amount of a compound of Formula (I):
or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m is an integer from 2 to 5, and n is an integer from 3 to 8, X 1 and X 2 each independently represent a sulfur atom, oxygen atom, sulfinyl group or a sulfonyl group, provided that X 1 and X 2 are not simultaneously oxygen atom.
10 . The method of claim 9 , in which the compound of Formula (I) is of Formula (IA)
11 . The method of claim 9 , in which the metabolite of the compound of Formula (I) is a compound of Formula (IB):
12 . The method of claim 9 , in which the compound is administered orally.
13 . The method of claim 12 , in which the compound is administered as a tablet or a capsule.
14 . The method of claim 10 , in which the compound is present in an orthorhombic polymorphic form A that is substantially free of other polymorphic forms.
15 . The method of claim 9 , in which the compound is administered as a liquid dosage form.
16 . The method of claim 9 , in which the compound is administered in an amount from 100 to 4,000 mg/day, divided into one, two, or three portions.Join the waitlist — get patent alerts
Track US2015005385A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.